AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19358790 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR 300 mg/day
Number of subjects: 612
Study 19358790 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day
Number of subjects: 612
Study 19358790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 612
Study 17575751 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic interventions in transplant recipients
Number of subjects: 0
Study 17575751 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic interventions
Number of subjects: 0
Study 12752867 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group changed body position hourly (supine, right side-lying, left side-lying) for the first 7 hours after coronary angiography.
Number of subjects: 419
Study 12752867 — intervention group
Group type: COMPARATOR
Intervention: Control group received usual care, remaining supine and flat for 8-24 hours with the affected leg straight.
Number of subjects: 419
Study 12752867 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups experienced increased back pain intensity with longer time on bedrest.
Number of subjects: 419
Study 12752867 — intervention group
Group type: COMPARATOR
Intervention: Experimental group vs Control group regarding vascular complications (bleeding at femoral site).
Number of subjects: 419
Study 11251497 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuity of midwifery care (team care)
Number of subjects: 1000
Study 11251497 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1000
Study 9065356 — intervention group
Group type: EXPERIMENTAL
Intervention: Early follow-up service provided by OXHIS at 7-10 days post-injury
Number of subjects: 579
Study 9065356 — intervention group
Group type: COMPARATOR
Intervention: Postal information alone
Number of subjects: 579
Study 9065356 — intervention group
Group type: COMPARATOR
Intervention: Telephone contact, advice and information
Number of subjects: 579
Study 9065356 — intervention group
Group type: COMPARATOR
Intervention: In-person assessment and advice
Number of subjects: 579
Study 9065356 — intervention group
Group type: COMPARATOR
Intervention: Telephone support
Number of subjects: 579
Study 9065356 — intervention group
Group type: COMPARATOR
Intervention: Further face-to-face contact
Number of subjects: 579
Study 8417384 — intervention group
Group type: EXPERIMENTAL
Intervention: Deprenyl (10 mg per day)
Number of subjects: 800
Study 8417384 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocopherol (2000 IU per day)
Number of subjects: 800
Study 8417384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800
Study 8417384 — intervention group
Group type: EXPERIMENTAL
Intervention: Active deprenyl and tocopherol placebo
Number of subjects: 800
Study 8417384 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tocopherol and deprenyl placebo
Number of subjects: 800
Study 3530158 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine 600 mg base once, followed by proguanil 100 mg per day
Number of subjects: 200
Study 3530158 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron 60 mg daily
Number of subjects: 200
Study 3530158 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 1 mg daily
Number of subjects: 200
Study 3530158 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron plus folic acid
Number of subjects: 200
Study 3530158 — intervention group
Group type: COMPARATOR
Intervention: No active treatment (Control group)
Number of subjects: 200
Study 3530158 — intervention group
Group type: EXPERIMENTAL
Intervention: Proguanil (as part of the antimalarial regimen)
Number of subjects: 200
Study 30428521 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling at 45 min after baseline
Number of subjects: 78
Study 30428521 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling at 15 min after baseline
Number of subjects: 78
Study 30428521 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control
Number of subjects: 78
Study 26615182 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical decision support for renal dosage adjustments
Number of subjects: 1278
Study 26615182 — intervention group
Group type: COMPARATOR
Intervention: Usual workflow (Control)
Number of subjects: 1278
Study 26615182 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective alerts
Number of subjects: 1278
Study 26615182 — intervention group
Group type: EXPERIMENTAL
Intervention: Look-back alerts
Number of subjects: 1278
Study 24618630 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasopore® packing
Number of subjects: 47
Study 24618630 — intervention group
Group type: COMPARATOR
Intervention: No nasal packing (Control)
Number of subjects: 47
Study 22539568 — intervention group
Group type: EXPERIMENTAL
Intervention: bilateral continuous theta burst stimulation (cTBS) at the temporal cortex
Number of subjects: 48
Study 22539568 — intervention group
Group type: EXPERIMENTAL
Intervention: bilateral continuous theta burst stimulation (cTBS) at the temporoparietal cortex
Number of subjects: 48
Study 22539568 — intervention group
Group type: COMPARATOR
Intervention: sham condition behind the mastoid
Number of subjects: 48
Study 20304677 — intervention group
Group type: EXPERIMENTAL
Intervention: Kyphoplasty
Number of subjects: 40
Study 20304677 — intervention group
Group type: COMPARATOR
Intervention: Control (no kyphoplasty)
Number of subjects: 40
Study 17382150 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasively estimated International Continence Society obstruction classification
Number of subjects: 150
Study 17382150 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasively assessed bladder outlet obstruction probability
Number of subjects: 150
Study 17382150 — intervention group
Group type: COMPARATOR
Intervention: Treatment recommendations based on BOO classification
Number of subjects: 150
Study 17382150 — intervention group
Group type: COMPARATOR
Intervention: Treatment recommendations based on BOO probability
Number of subjects: 150
Study 16333173 — intervention group
Group type: COMPARATOR
Intervention: Single plane incision (1.5 mm)
Number of subjects: 240
Study 16333173 — intervention group
Group type: COMPARATOR
Intervention: Two plane incision (2 mm)
Number of subjects: 240
Study 16333173 — intervention group
Group type: COMPARATOR
Intervention: Three plane incision (2.5 mm)
Number of subjects: 240
Study 16333173 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscoelastic injection
Number of subjects: 240
Study 16333173 — intervention group
Group type: COMPARATOR
Intervention: No viscoelastic injection
Number of subjects: 240
Study 16333173 — intervention group
Group type: EXPERIMENTAL
Intervention: Incision length 2 mm
Number of subjects: 240
Study 16333173 — intervention group
Group type: EXPERIMENTAL
Intervention: Incision length 2.5 mm
Number of subjects: 240
Study 12477503 — intervention group
Group type: EXPERIMENTAL
Intervention: Long‐protocol pituitary down‐regulation followed by FSH stimulation; vaginal progesterone for luteal support
Number of subjects: 18
Study 12477503 — intervention group
Group type: COMPARATOR
Intervention: Control group (no OHSS)
Number of subjects: 18
Study 9445205 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (400 mg 3 times a day orally, n=20)
Number of subjects: 40
Study 9445205 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=20)
Number of subjects: 40
Study 7612367 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 0
Study 7612367 — intervention group
Group type: COMPARATOR
Intervention: Open cholecystectomy
Number of subjects: 0
Study 2196494 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal ultrasonography with a 240 degrees scanning angle
Number of subjects: 201
Study 2196494 — intervention group
Group type: COMPARATOR
Intervention: Digital examination
Number of subjects: 201
Study 92877 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (Trasylol) administered intravenously
Number of subjects: 25
Study 92877 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 25
Study 31422392 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin combined with 5 mg imipramine at bedtime
Number of subjects: 40
Study 31422392 — intervention group
Group type: COMPARATOR
Intervention: Desmopressin alone
Number of subjects: 40
Study 28755307 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetition of Epley maneuver
Number of subjects: 144
Study 28755307 — intervention group
Group type: COMPARATOR
Intervention: Switch to Semont maneuver
Number of subjects: 144
Study 25761943 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal gastric bypass (150 cm alimentary limb)
Number of subjects: 115
Study 25761943 — intervention group
Group type: COMPARATOR
Intervention: Distal gastric bypass (150 cm common channel)
Number of subjects: 115
Study 24167552 — intervention group
Group type: EXPERIMENTAL
Intervention: Altitude 1630 m
Number of subjects: 44
Study 24167552 — intervention group
Group type: EXPERIMENTAL
Intervention: Altitude 2590 m
Number of subjects: 44
Study 24167552 — intervention group
Group type: COMPARATOR
Intervention: Baseline (490 m)
Number of subjects: 44
Study 21233404 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipifarnib and bortezomib combination
Number of subjects: 0
Study 19470174 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose risperidone
Number of subjects: 56
Study 19470174 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 56
Study 17185150 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft silicone tunneled catheters (ST)Caths
Number of subjects: 30
Study 17185150 — intervention group
Group type: COMPARATOR
Intervention: Twin polyurethane nontunneled femoral catheters
Number of subjects: 30
Study 16327534 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based pulmonary rehabilitation program
Number of subjects: 60
Study 11878034 — intervention group
Group type: EXPERIMENTAL
Intervention: Education outreach visits
Number of subjects: 0
Study 11878034 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminders
Number of subjects: 0
Study 11878034 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted strategies tailored to the particular setting
Number of subjects: 0
Study 11878034 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 10325282 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF‐1 concentrations in follicular fluid during ovulatory phase
Number of subjects: 27
Study 10325282 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF‐1 concentrations in follicular fluid at oocyte retrieval
Number of subjects: 27
Study 10325282 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF‐1 concentrations in plasma on day 9 after HCG
Number of subjects: 27
Study 10325282 — intervention group
Group type: COMPARATOR
Intervention: CSF‐1 concentrations in plasma during ovarian stimulation
Number of subjects: 27
Study 10325282 — intervention group
Group type: COMPARATOR
Intervention: CSF‐1 concentrations in blood during the menstrual cycle
Number of subjects: 27
Study 8756739 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostatic carcinoma patients
Number of subjects: 20
Study 8756739 — intervention group
Group type: COMPARATOR
Intervention: Benign prostatic hyperplasia patients (control)
Number of subjects: 20
Study 1840337 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Number of subjects: 2
Study 1840337 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine
Number of subjects: 2
Study 1840337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 7288001 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal attribution manipulations
Number of subjects: 0
Study 7288001 — intervention group
Group type: EXPERIMENTAL
Intervention: General attribution conditions
Number of subjects: 0
Study 7288001 — intervention group
Group type: COMPARATOR
Intervention: External attribution conditions
Number of subjects: 0
Study 7288001 — intervention group
Group type: COMPARATOR
Intervention: Specific attribution conditions
Number of subjects: 0
Study 31133061 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ketamine (0.3 mg/kg in 0.9% sodium chloride, 100 ml bag) in addition to standard intravenous hydration
Number of subjects: 0
Study 31133061 — intervention group
Group type: COMPARATOR
Intervention: Standard dose of morphine (0.1 mg/kg in 0.9% sodium chloride, 100 ml bag) in addition to standard intravenous hydration
Number of subjects: 0
Study 28195835 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based Neonatal Resuscitation Program (NRP) curriculum
Number of subjects: 25
Study 28195835 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolling refresher training at varied time intervals
Number of subjects: 25
Study 26341706 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-virus laboratory-generated PCR bundle
Number of subjects: 0
Study 26341706 — intervention group
Group type: COMPARATOR
Intervention: 17-virus FilmArray PCR platform
Number of subjects: 0
Study 23800106 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Early Supported Discharge (VESD)
Number of subjects: 44
Study 23800106 — intervention group
Group type: COMPARATOR
Intervention: Ordinary discharge
Number of subjects: 44
Study 21067716 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial biopsy assessed for the presence of nucleolar channel systems (NCSs) by indirect immunofluorescence.
Number of subjects: 175
Study 19225434 — intervention group
Group type: EXPERIMENTAL
Intervention: ACUVUE 2
Number of subjects: 28
Study 19225434 — intervention group
Group type: EXPERIMENTAL
Intervention: ACUVUE ADVANCE
Number of subjects: 28
Study 19225434 — intervention group
Group type: EXPERIMENTAL
Intervention: O2OPTIX
Number of subjects: 28
Study 19225434 — intervention group
Group type: EXPERIMENTAL
Intervention: NIGHT & DAY
Number of subjects: 28
Study 19225434 — intervention group
Group type: EXPERIMENTAL
Intervention: PureVision
Number of subjects: 28
Study 17088002 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic
Number of subjects: 4102
Study 17088002 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic tablets
Number of subjects: 4102
Study 17088002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4102
Study 15178687 — intervention group
Group type: EXPERIMENTAL
Intervention: Isohumulones (isohumulone and isocohumulone)
Number of subjects: 0
Study 15178687 — intervention group
Group type: EXPERIMENTAL
Intervention: Isohumulones
Number of subjects: 0
Study 15178687 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone
Number of subjects: 0
Study 12529070 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol beverage
Number of subjects: 204
Study 12529070 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 204
Study 9693288 — intervention group
Group type: EXPERIMENTAL
Intervention: Plate haptic silicone lens (Silens PH)
Number of subjects: 100
Study 9693288 — intervention group
Group type: COMPARATOR
Intervention: Three-piece silicone intraocular lens (CeeOn)
Number of subjects: 100
Study 9693288 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Plate haptic and Three-piece)
Number of subjects: 100
Study 8595925 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with SLE
Number of subjects: 37
Study 8595925 — intervention group
Group type: COMPARATOR
Intervention: Healthy normal subjects
Number of subjects: 37
Study 2653041 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal corticosteroids
Number of subjects: 27
Study 2653041 — intervention group
Group type: COMPARATOR
Intervention: Tocolysis, prophylactic antibiotics, and other interventions
Number of subjects: 27
Study 365249 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable constant‐cuff blood pressure feedback technique
Number of subjects: 30
Study 365249 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation-relaxation
Number of subjects: 30
Study 365249 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 30
Study 31859246 — intervention group
Group type: EXPERIMENTAL
Intervention: CDKI plus aromatase inhibitor
Number of subjects: 4200
Study 31859246 — intervention group
Group type: EXPERIMENTAL
Intervention: CDKI plus fulvestrant
Number of subjects: 4200
Study 31859246 — intervention group
Group type: EXPERIMENTAL
Intervention: CDKI plus fulvestrant (second-line and beyond)
Number of subjects: 4200
Study 31859246 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus aromatase inhibitor
Number of subjects: 4200
Study 31859246 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus fulvestrant
Number of subjects: 4200
Study 30728027 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 plus radical surgery
Number of subjects: 70
Study 30728027 — intervention group
Group type: COMPARATOR
Intervention: D2 radical surgery
Number of subjects: 70
Study 28898485 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (10 Hz, 5 s-on, 10 s-off, 100% motor threshold, 3,000 pulses)
Number of subjects: 11
Study 28898485 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 11
Study 25495101 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehydration (RE: water equal to 175% of body mass loss (BML))
Number of subjects: 10
Study 25495101 — intervention group
Group type: COMPARATOR
Intervention: Hypohydration (HYPO: 200 ml water)
Number of subjects: 10
Study 25495101 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehydration (RE)
Number of subjects: 10
Study 25495101 — intervention group
Group type: COMPARATOR
Intervention: Hypohydration (HYPO)
Number of subjects: 10
Study 23352582 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT-O
Number of subjects: 154
Study 21889073 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated miswaks impregnated in 0.5% sodium fluoride (test group, n=19)
Number of subjects: 37
Study 21889073 — intervention group
Group type: COMPARATOR
Intervention: Nonfluoridated miswaks (control group, n=18)
Number of subjects: 37
Study 19001447 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured therapy interruption (STI)
Number of subjects: 120
Study 19001447 — intervention group
Group type: COMPARATOR
Intervention: Continuous HAART
Number of subjects: 120
Study 16882745 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyline (long‐acting GnRH‐antagonist) every 2 weeks
Number of subjects: 13
Study 16882745 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyline plus testosterone (T) gel (10 mg/d)
Number of subjects: 13
Study 16882745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 15172401 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg loading dose)
Number of subjects: 23
Study 11284483 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol maleate 0.50%
Number of subjects: 40
Study 11284483 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol HCl 0.50%
Number of subjects: 40
Study 11284483 — intervention group
Group type: EXPERIMENTAL
Intervention: Carteolol 1%
Number of subjects: 40
Study 11284483 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobunolol 0.50%
Number of subjects: 40
Study 9205920 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioactive glass (Perioglas)
Number of subjects: 20
Study 9205920 — intervention group
Group type: COMPARATOR
Intervention: Surgical debridement only (Control)
Number of subjects: 20
Study 8387176 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin, ifosfamide, and cisplatin (MIC)
Number of subjects: 74
Study 8387176 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy in combination with MIC
Number of subjects: 74
Study 8387176 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 74
Study 2450244 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 30 mg t.i.d. (three times a day)
Number of subjects: 12
Study 2450244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2450244 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine combined with enalapril
Number of subjects: 12
Study 2450244 — intervention group
Group type: COMPARATOR
Intervention: Placebo with enalapril
Number of subjects: 12
Study 29381241 — intervention group
Group type: EXPERIMENTAL
Intervention: incisional negative pressure wound therapy (iNPWT)
Number of subjects: 33
Study 29381241 — intervention group
Group type: COMPARATOR
Intervention: standard dressing
Number of subjects: 33
Study 27377115 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anaesthetic agent plus low-power laser
Number of subjects: 66
Study 27377115 — intervention group
Group type: COMPARATOR
Intervention: Topical anaesthetic agent (benzocaine)
Number of subjects: 66
Study 25382325 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizoribine (MZR) 300 mg every other day
Number of subjects: 90
Study 25382325 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 2 g per day in two divided doses
Number of subjects: 90
Study 25382325 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cyclophosphamide (CYC) 0.5 g every 2 weeks
Number of subjects: 90
Study 25382325 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizoribine (MZR)
Number of subjects: 90
Study 25382325 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 90
Study 25382325 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cyclophosphamide (CYC)
Number of subjects: 90
Study 25382325 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF) or Intravenous cyclophosphamide (CYC)
Number of subjects: 90
Study 25382325 — intervention group
Group type: COMPARATOR
Intervention: Mizoribine (MZR) or Mycophenolate mofetil (MMF)
Number of subjects: 90
Study 25382325 — intervention group
Group type: COMPARATOR
Intervention: CYC
Number of subjects: 90
Study 23548682 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminiscing training (four weekly in-home sessions in elaborative and emotion-rich reminiscing)
Number of subjects: 44
Study 23548682 — intervention group
Group type: COMPARATOR
Intervention: Control (wait-list condition)
Number of subjects: 44
Study 23548682 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminiscing training
Number of subjects: 44
Study 23548682 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 44
Study 20610096 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalens AT‐45 IOL accommodating IOL
Number of subjects: 25
Study 19033608 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 13
Study 19033608 — intervention group
Group type: COMPARATOR
Intervention: Fluid restriction (FR)
Number of subjects: 13